Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization1 6951 2422 006757--
Entreprise Value (EV)1 6951 2421 891672416467
P/E ratio -13,6x-13,6x-16,7x-16,2x-13,6x-13,2x
Yield ------
Capitalization / Revenue --96,7x11,3x7,23x6,67x
EV / Revenue --91,1x10,1x3,97x4,12x
EV / EBITDA -16,1x-15,0x-15,8x-7,17x-4,56x-3,48x
Price to Book -6,24x18,8x6,27x3,05x3,24x
Nbr of stocks (in thousands) 34 19439 72840 51443 644--
Reference price (USD) 20,331,349,517,417,417,4
Announcement Date 03/22/201903/12/202002/25/2021---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales1 --20,866,8105113
EBITDA1 -43,2-82,8-120-93,8-91,2-134
Operating profit (EBIT)1 -43,2-83,0-120-80,2-73,0-86,3
Operating Margin ---578%-120%-69,7%-76,1%
Pre-Tax Profit (EBT)1 -43,3-81,0-119-46,6-48,3-106
Net income1 -43,3-81,0-119-48,8-58,6-69,5
Net margin ---575%-73,0%-55,9%-61,2%
EPS2 -1,50-2,30-2,97-1,07-1,27-1,31
Dividend per Share2 ------
Announcement Date 03/22/201903/12/202002/25/2021---
1 USD in Million
2 USD
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2
Net sales1 5,3811,08,9711,113,938,6
EBITDA1 -28,1-22,5-28,6-31,0--
Operating profit (EBIT)1 -28,3-22,7-28,7-30,4-26,1-25,3
Operating Margin -525%-207%-320%-273%-187%-65,5%
Pre-Tax Profit (EBT)1 33,4-22,9-28,9-28,4-25,8-24,7
Net income1 33,4-22,9-28,9-30,1-26,0-25,2
Net margin 621%-209%-322%-271%-187%-65,3%
EPS2 0,75-0,53-0,66-0,68-0,61-0,29
Dividend per Share ------
Announcement Date 05/06/202108/05/202111/04/2021---
1 USD in Million
2 USD
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt1 ------
Net Cash position1 --11585,0341290
Leverage (Debt / EBITDA) --0,96x0,91x3,74x2,16x
Free Cash Flow1 --75,5-91,4-41,0-61,0-38,0
ROE (Net Profit / Equities) -38,9%-47,7%-78,3%-45,6%-26,1%-40,3%
Shareholders' equity1 111170152107224173
ROA (Net Profit / Asset) --44,0%-68,5%-29,8%-37,5%-50,6%
Assets1 -184174164156137
Book Value Per Share2 -5,012,642,775,685,36
Cash Flow per Share2 -1,43-2,09-2,27-0,78-0,63-
Capex1 0,231,970,18---
Capex / Sales --0,84%---
Announcement Date 03/22/201903/12/202002/25/2021---
1 USD in Million
2 USD
Key data
Capitalization (USD) 757 221 942
Net sales (USD) 20 750 000
Number of employees 125
Sales / Employee (USD) 166 000
Free-Float 83,8%
Free-Float capitalization (USD) 634 298 563
Avg. Exchange 20 sessions (USD) 5 149 762
Average Daily Capital Traded 0,68%
EPS & Dividend